米氮平和阿米替林治疗躯体化障碍的对照研究

A Controlled Study of Mirtazapine and Amitrptyline in Somatization

目的:比较米氮平和阿米替林治疗强迫症的疗效和不良反应。方法:以CCMD-2作为诊断标准,用SCL-90,TESS量表评定临床疗效和不良反应,对60例患者进行8周治疗。结果:米氮平与阿米替林疗效相近,两者无显著差异(P>0·05),米氮平不良反应明显少于阿米替林(P<0·01),而且耐受性好。结论:米氮平治疗躯体化障碍与阿米替林相当,但米氮平具有口服剂量小,给药方法简便,不良反应等优点。

OBJECTIVE ： To compare curative effects, adverse reactions and the safety of mirtazapine and amitriptyline in the treatment of obsession . METHODS ： 60 patients with somatization disorder were randomly divided into study group （n = 30, took mirtazapine） and control group （n = 30, took amitriptyline）. Curative effects were evaluated with SCL- 90 before and at the end of treatment , at the 2nd, fourth and eighth week of treatment, respectively. Adverse reactions were evaluated with TESS. RESULTS： Curative effects of mirtazapine and amitriptyline were 93.3 % and 90% respectively, there was no significant difference（ P 〉 0.05 ）. Adverse reactions of the former were significantly fewer than that of the latter （P 〈 0.01 ）, and it also had good tolerance. CONCLUSION： Curative effect of mirtazapine is correspond to that of amitriptyline, but adverse reactions are fewer. Mirtazapine is a safe and effective new antidepressant.